BioDeal 360™

Overview

Wescadia Group’s BioDeal 360™ provides analysis, commentary, insight, and opinion on deal activity in the Australian life science sector.

Volume 1, Number 1, December 2012

Pages: 23
Figures: 2
Tables: 2
Price: Free

Summary

The purpose of this report is to:

  • Provide an overview of selected deals such as in-licensing, out-licensing or mergers and acquisitions (M&A) by Australian life science companies in 2012.
  • Understand the strategic significance of the deals.

Questions Answered:

  • Which pharmaceutical, biotechnology, medical device and diagnostic players in Australia have been active in deals? What are the reasons for the different level of deal activity between the different players?
  • What is the rationale for transactions between Australian life science companies and their partners? What approaches maximize the value of transactions between Australian life science companies and their partners?
  • How can Australian life science companies capitalize on the challenges facing big pharma?

Companies Mentioned:

AstraZeneca
Bionomics
Cochlear
CSL
Eclipse Therapeutics
Geron Corporation
Immuron
Ironwood Pharmaceuticals
Marinova
Neuron Systems
Optimer Pharmaceuticals
Paladin Laboratories
pSivida
ResMed
Siemens
Sienna Cancer Diagnostics
Specialised Therapeutics Australia
Starpharma
Stemtech International
Umbian
Universal Biosensors

What To Do Next:

Please contact us if you would like further information or would like to order a copy of this free report.